NICE says no to Celgene's myeloma drug Imnovid; Sucampo, Takeda extend Amitiza pact;

> The U.K.'s cost-effectiveness watchdog has issued preliminary draft guidance not recommending Celgene's ($CELG) multiple myeloma treatment Imnovid. More

> Sucampo and Takeda have extended their licensing agreement for constipation drug Amitiza. Release

> ViiV Healthcare has won approval for HIV pill Triumeq in Canada. Release

> Scotland has recommended Novartis' ($NVS) Gilenya for patients with a severe form of relapsing multiple sclerosis. Report

> Retrophin has agreed to divest ketamine, Syntocinon Nasal Spray, and Vecamyl to Turing Pharmaceuticals. Release

And Finally... Pfizer ($PFE) has joined up with leaders in the breast cancer community to expand the breast cancer dialogue to include metastatic breast cancer. More

Suggested Articles

GI cancers are stubborn, as plenty of oncology drugmakers know. But BMS' Opidivo has broken through with two potentially practice-changing trials.

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

The Tecentriq-Avastin-chemo cocktail did slightly better in PD-L1-positive patients but still failed to cross the statistical significance bar.